Genetically Low Vitamin D Levels, Bone Mineral Density, and Bone Metabolism Markers: a Mendelian Randomisation Study

BackgroundResistin is a relatively novel adipokine that has a role in bone remodeling and may regulate bone mineral density (BMD). Vitamin D and adipokines have a dynamic role in the body’s various metabolic processes, including bone metabolism, and may alter bone metabolism in relation to each other. This study aimed to investigate the association between vitamin D and serum resistin levels in postmenopausal non-osteoporotic and osteoporotic females.MethodsThis correlational analytical study was conducted on 161 postmenopausal females, divided into two groups, non-osteoporotic and osteoporotic, between 50–70 years. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry (DXA) scan. Serum resistin and vitamin D levels were analyzed by enzyme-linked immunosorbent assay (ELISA) method. Serum calcium, phosphate, and alkaline phosphatase with spectrophotometry. A correlation was checked using spearman’s rho correlation coefficient, and multivariate stepwise regression analysis was used to predict serum resistin levels.ResultsPostmenopausal females (n=161) having sufficient, insufficient and deficient levels of vitamin D were 87 (54.0%), 64 (39.8%), and 10 (6.2%), respectively. Lumbar spine BMD (p < 0.001), total hip BMD (p < 0.001), and serum resistin levels (p < 0.001) were significantly different between the two groups. There was a significant negative correlation between serum resistin and vitamin D in postmenopausal females (rho = -0.182, p = 0.021) and osteoporotic group (rho = -0.253, p = 0.019) but non-significant in non-osteoporotic group (rho = -0.077, p = 0.509). Serum vitamin D was found to be independent predictor of serum resistin levels, accounting for only 3% variance.ConclusionSerum vitamin D levels were low while serum resistin levels were high in postmenopausal osteoporotic females and vitamin D is a negative predictor of serum resistin levels.

Download Full-text

Assessment of Bone Metabolism and Bone Mineral Density in Children with Helicobacter pylori Infection

Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy ◽

10.5222/bmj.2020.35229 ◽

2020 ◽

Author(s):

Nafiye Urgancı ◽

Derya Kalyoncu

Keyword(s):

Bone Mineral Density ◽

Vitamin D ◽

Helicobacter Pylori ◽

Bone Metabolism ◽

Bone Mineral ◽

Biochemical Parameters ◽

Mineral Density ◽

Vitamin D Levels ◽

Significant Difference ◽

H Pylori

Objective: Gastrointestinal disorders may have negative impact on bone metabolism. The aim of the study was to evaluate bone metabolism and bone mineral density in children with Helicobacter pylori (H. pylori) infection. Method: A total of 100 children (mean age: 13.69±2.44 years, M/F: 0.66) with chronic gastritis were divided into two groups according to presence of H. pylori infection and were tested for biochemical parameters such as calcium, phosphorus, magnesium, alkaline phosphatase, parathyroid hormone and vitamin D. Bone mineral density was measured at lumbar spine in all of the patients by dual-energy x-ray absorptiometry (DXA). Results: 48 of 72 patients with H. pylori and 16 of 28 patients without H. pylori had low vitamin D levels (p=0.35). The other biochemical parameters were within normal limits in both groups. Bone mineral density was measured -0.16±2.25 g/cm2 in H. pylori-positive patients and -0.08±2.62 g/cm2 in H. pylori-negative patients (p=0.87). Only 2 patients with H. pylori and 1 without H. pylori had BMD z scores below -2.5 (p=1.00). Conclusion: No significant difference was observed in biochemical parameters of bone metabolism and bone mineral density between H.pylori-positive and H. pylori-negative children.

Download Full-text

P114 Effect of vitamin D on parathyroid hormone, serum calcium and bone mineral density in patients with primary hyperparathyroidism being managed conservatively

Rheumatology ◽

10.1093/rheumatology/keab247.110 ◽

2021 ◽

Vol 60 (Supplement_1) ◽

Author(s):

Mahrukh Khalid ◽

Vismay Deshani ◽

Khalid Jadoon

Keyword(s):

Bone Mineral Density ◽

Vitamin D ◽

Parathyroid Hormone ◽

Primary Hyperparathyroidism ◽

Bone Mineral ◽

Serum Calcium ◽

Mineral Density ◽

Neck Of Femur ◽

Vitamin D Levels ◽

Significant Difference

Abstract Background/Aims Vitamin D deficiency is associated with more severe presentation of primary hyperparathyroidism (PTHP) with high parathyroid hormone (PTH) levels and reduced bone mineral density (BMD). We analyzed data to determine if vitamin D levels had any impact on PTH, serum calcium and BMD at diagnosis and 3 years, in patients being managed conservatively. Methods Retrospective analysis of patients presenting with PHPT. Based on vitamin D level at diagnosis, patients were divided into two groups; vitamin D sufficient (≥ 50 nmol/L) and vitamin D insufficient (≤ 50 nmol/L). The two groups were compared for age, serum calcium and PTH levels at diagnosis and after mean follow up of 3 years. BMD at forearm and neck of femur (NOF) was only analyzed in the two groups at diagnosis, due to lack of 3 year’s data. Results There were a total of 93 patients, 17 males, mean age 70; range 38-90. Mean vitamin D level was 73.39 nmol/L in sufficient group (n = 42) and 34.48 nmol/L in insufficient group (n = 40), (difference between means -38.91, 95% confidence interval -45.49 to -32.33, p < 0.0001). There was no significant difference in age, serum calcium and PTH at the time of diagnosis. After three years, there was no significant difference in vitamin D levels between the two groups (mean vitamin D 72.17 nmol/L in sufficient group and 61.48 nmol/L in insufficient group). Despite rise in vitamin D level in insufficient group, no significant change was observed in this group in PTH and serum calcium levels. BMD was lower at both sites in vitamin D sufficient group and difference was statistically significant at NOF. Data were analyzed using unpaired t test and presented as mean ± SEM. Conclusion 50% of patients presenting with PHPT were vitamin D insufficient at diagnosis. Vitamin D was adequately replaced so that at 3 years there was no significant difference in vitamin D status in the two groups. Serum calcium and PTH were no different in the two groups at diagnosis and at three years, despite rise in vitamin D levels in the insufficient group. Interestingly, BMD was lower at forearm and neck of femur in those with sufficient vitamin D levels and the difference was statistically significant at neck of femur. Our data show that vitamin D insufficiency does not have any significant impact on PTH and calcium levels and that vitamin D replacement is safe in PHPT and does not impact serum calcium and PTH levels in the short term. Lower BMD in those with adequate vitamin D levels is difficult to explain and needs further research. Disclosure M. Khalid: None. V. Deshani: None. K. Jadoon: None.

Download Full-text

Protective effect of vitamin D3 on methylprednisolone acetate (MPA) induced loss of bone metabolism markers and bone mineral density in the lumbar spine of rat

Bone ◽

10.1016/j.bone.2006.01.095 ◽

2006 ◽

Vol 38 (3) ◽

pp. 19

Author(s):

A. Sobhani ◽

F. Moradi ◽

P. Pasbakhsh ◽

I.R. Kashani

Keyword(s):

Bone Mineral Density ◽

Lumbar Spine ◽

Protective Effect ◽

Bone Metabolism ◽

Bone Mineral ◽

Vitamin D3 ◽

Methylprednisolone Acetate ◽

Mineral Density ◽

Bone Metabolism Markers

Download Full-text

Management of bone metabolism in epilepsy

Ideggyógyászati Szemle ◽

10.18071/isz.74.0257 ◽

2021 ◽

Vol 74 (7-8) ◽

pp. 257-265

Author(s):

Firdevs Ezgi Uçan Tokuç ◽

Fatma Genç ◽

Abidin Erdal ◽

Yasemin Biçer Gömceli

Keyword(s):

Bone Mineral Density ◽

Vitamin D ◽

Bone Metabolism ◽

Bone Mineral ◽

Outpatient Clinic ◽

Bone Mineralization ◽

Mineral Density ◽

Low Bone Mineral Density ◽

Increased Risk ◽

Significant Difference

Many systemic problems arise due to the side effects of antiepileptic drugs (AEDs) used in epilepsy patients. Among these adverse effects are low bone mineral density and increased fracture risk due to long-term AED use. Although various studies have supported this association with increased risk in recent years, the length of this process has not been precisely defined and there is no clear consensus on bone density scanning, intervals of screening, and the subject of calcium and vitamin D supplementation. In this study, in accordance with the most current recommendations, our applications and data, including the detection of possible bone mineralization disorders, treatment methods, and recommendations to prevent bone mineralization disorders, were evaluated in epilepsy patients who were followed up at our outpatient clinic. It was aimed to draw attention to the significance of management of bone metabolism carried out with appropriate protocols. Epilepsy patients were followed up at the Antalya Training and Research Hospital Department of Neurology, Epilepsy Outpatient Clinic who were at high risk for osteoporosis (use of valproic acid [VPA] and enzyme-inducing drugs, using any AED for over 5 years, and postmenopausal women) and were evaluated using a screening protocol. According to this protocol, a total of 190 patients suspected of osteoporosis risk were retrospectively evaluated. Four patients were excluded from the study due to secondary osteoporosis. Of the 186 patients who were included in the study, 97 (52.2%) were women and 89 (47.8%) were men. Prevalence of low bone mineral density (BMD) was 42%, in which osteoporosis was detected in 11.8% and osteopenia in 30.6% of the patients. Osteoporosis rate was higher at the young age group (18-45) and this difference was statistically significant (p=0.018). There was no significant difference between male and female sexes according to osteoporosis and osteopenia rates. Patients receiving polytherapy had higher osteoporosis rate and lower BMD compared to patients receiving monotherapy. Comparison of separate drug groups according to osteoporosis rate revealed that osteoporosis rate was highest in patient groups using VPA+ carbamazepine (CBZ) (29.4%) and VPA polytherapy (19.4%). Total of osteopenia and osteoporosis, or low BMD, was highest in VPA polytherapy (VPA+ non-enzyme-inducing AED [NEID]) and CBZ polytherapy (CBZ+NEID) groups, with rates of 58.3% and 55.1%, respectively. In addition, there was no significant difference between drug groups according to bone metabolism markers, vitamin D levels, and osteopenia-osteoporosis rates. Assuming bone health will be affected at an early age in epilepsy patients, providing lifestyle and diet recommendations, avoiding polytherapy including VPA and CBZ when possible, and evaluating bone metabolism at regular intervals are actions that should be applied in routine practice.

Download Full-text

Erratum to: Bone mineral density and vitamin D levels in erythropoietic protoporphyria

Endocrine ◽

10.1007/s12020-013-9955-5 ◽

2013 ◽

Vol 44 (3) ◽

pp. 808-808

Author(s):

Gonzalo Allo ◽

Maria del Carmen Garrido-Astray ◽

Manuel Méndez ◽

Rafael Enríquez De Salamanca ◽

Guillermo Martínez ◽

...

Keyword(s):

Bone Mineral Density ◽

Vitamin D ◽

Bone Mineral ◽

Mineral Density ◽

Erythropoietic Protoporphyria ◽

Vitamin D Levels

Download Full-text

Vitamin D and bone mineral density status among postmenopausal Bangladeshi women

IMC Journal of Medical Science ◽

10.3329/imcjms.v12i2.39660 ◽

2019 ◽

Vol 12 (2) ◽

pp. 44-49

Author(s):

AKM Shaheen Ahmed ◽

Wasim Md Mohosin Ul Haque ◽

Khwaja Nazim Uddin ◽

Fadlul Azim Abrar ◽

Farhana Afroz ◽

...

Keyword(s):

Bone Mineral Density ◽

Vitamin D ◽

Postmenopausal Women ◽

Bone Mineral ◽

Age Groups ◽

Urban Hospital ◽

Mineral Density ◽

Cross Sectional ◽

Serum Ipth ◽

Vitamin D Levels

Background and objectives: Low vitamin D is a global problem in all age groups as is osteoporosis in postmenopausal women. The present study was carried out in an urban hospital to assess serum 25-hydroxyvitamin D [25(OH)D] level and bone mineral density (BMD) in postmenopausal women (PMW) and to evaluate correlation between serum 25(OH)D levels and BMD. Methods: A single center cross-sectional study was conducted among 133 apparently healthy PMW aged 45 years and above with the history of complete cessation of menstruation over a period of more than 1 year. Serum 25(OH)D, BMD and serum intact parathyroid hormone (iPTH) were determined. Patients having both vitamin D and BMD values were analyzed for correlations. Similarly, correlation of vitamin D, iPTH and BMD were determined. Results: Among the study population, 63 (47.4%) had deficient (<20 ng/ml), 46 (34.6%) had insufficient (20-30ng/ml) and 24(18%) had sufficient (30-100ng/ml) levels of serum 25(OH)D. Among the 121 patients whose BMD was done, 52 (43.0%) and 60 (49.6%) had osteoporosis and osteopenia respectively. Serum iPTH levels were normal in 34 (89.5%) patients. The proportion of osteopenia and osteoporosis in vitamin D deficient group were 44.1% and 50.8% and in insufficient group 47.5 and 45.0%, respectively. Age had significant negative correlation with BMD value (r=-0.246, p=.005) and significant positive correlation with serum iPTH (r=0.358, p=.024). There was no statistically significant influence of serum 25(OH)D or iPTH on occurrence of osteoporosis (P=0.322 and P=0.592 respectively). Conclusion: A large proportion of postmenopausal women had low vitamin D levels and as well as osteopenia and osteoporosis. Low vitamin D level coexisted with low BMD. However, there was no correlation between serum 25(OH)D levels and BMD status. IMC J Med Sci 2018; 12(2): 44-49

Download Full-text